Cosmos Health (COSM) Fundamentals 2026 — Revenue Analysis | SniperIQ
Cosmos Health (COSM) is a GR-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Cosmos Health's market cap?
Cosmos Health (COSM) has a market capitalization of approximately
What is Cosmos Health's P/E ratio?
Cosmos Health's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 0.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Cosmos Health?
Cosmos Health runs a net profit margin of -30.4%, a gross margin of 10.4%, and an operating margin of -25.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Cosmos Health generate?
Cosmos Health reported revenue of $65M for fiscal year 2025, with net income of -
Does Cosmos Health pay a dividend?
Cosmos Health does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Cosmos Health financially healthy?
Cosmos Health carries a debt-to-equity ratio of 0.88x and a current ratio of 1.08x, with a market beta of 4.15. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Cosmos Health a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Cosmos Health (COSM) the key facts are: market cap
Track Cosmos Health's full fundamentals live
Get Cosmos Health's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.